ViAqua Therapeutics Ltd.

ViAqua Therapeutics is a biotechnology company based in Haifa, Israel, founded in 2014. The company focuses on disease management in the aquaculture industry, providing effective and affordable health management solutions for aquaculture diseases.

ViAqua's main product is a biotechnology-based oral delivery platform that uses encapsulated RNA particles in feed. Their initial offering is a feed supplement that enhances disease resistance in shrimp against the White Spot Shrimp Virus (WSSV). This solution aims to improve production stability for farmers and reduce disease risk. The technology has potential applications for other aquaculture species in the future.

The company has formed a commercial partnership with Skretting, a Nutreco company, to develop and market its products. ViAqua is currently scaling production to launch its first product, with a primary focus on shrimp production. The leadership team includes co-founders Shai Ufaz, Ph.D., and Shai Einbinder, Ph.D., along with Chris Beattie, Ph.D., who brings extensive experience in the aquaculture industry. ViAqua is at the seed investment stage.